Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q86YS7

UPID:
C2CD5_HUMAN

ALTERNATIVE NAMES:
C2 domain-containing phosphoprotein of 138 kDa

ALTERNATIVE UPACC:
Q86YS7; B4DJ03; B4DRN7; B7ZLL0; F5H2A1; F5H5R1; O60280; Q17RY7; Q7Z619; Q86SU3

BACKGROUND:
The C2 domain-containing protein 5, alternatively named as a 138 kDa phosphoprotein, is indispensable for insulin-mediated glucose uptake. It orchestrates the movement of SLC2A4/GLUT4 glucose transporters to the cell surface in fat cells, a process vital for glucose regulation. The protein's ability to bind to membranes in the presence of calcium is crucial for the fusion of glucose storage vesicles with the plasma membrane.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of C2 domain-containing protein 5 unveils potential avenues for therapeutic intervention. Given its central role in glucose management, targeting this protein could lead to innovative treatments for metabolic diseases, highlighting its significance in drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.